This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schreiber, K Articles by Sorensen, P S Search for Related Content PubMed PubMed Citation Articles by Schreiber, K Articles by Sorensen, P S Social Bookmarking                         What's this?

Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E)

Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

A B Oturai

Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, oturai{at}dadlnet.dk

L P Ryder

Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

H O Madsen

Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

O S Jørgensen

Laboratory of Neuropsychiatry, Department of Pharmacology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

A Svejgaard

Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

P S Sorensen

Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

As the understanding of the autoimmune inflammatory response in multiple sclerosis (MS) expands, polymorphic genes involved in this process become possible candidates that may determine the severity of disease. Therefore, three candidate genes DRB1*1501, CCR5 and apolipoprotein E (APOE) were examined in a population-based patient sample (n=70) to assess an association between disease progression measured by clinical disability and MRI parameters. The total lesion area (TLA) on T2-weighted images was measured with a semi-automated threshold technique. Patients with the CCR5D32 allele showed a non-significant trend towards a smaller lesion burden (TLA/years duration), but were not associated to a milder EDSS/years duration. Our data support previous assumptions of a modulation of severity in MS by the CCR5D32 genotype, which may convey less inflammation and tissue destruction. Carriers of the DRB1*1501 and APOE-e4 alleles did not reveal more severe disease progression, neither by the EDSS/years of duration nor by the TLA/years duration. This study was performed on a population-based sample in a genetically homogeneous Danish population but, due to the limited number of patients examined, weak associations between candidate genes and disease variables cannot be excluded.

Key Words: APOE • CCR532 • HLA • MRI • MS

Multiple Sclerosis, Vol. 8, No. 4, 295-298 (2002)
DOI: 10.1191/1352458502ms816oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B A Parmenter, D R Denney, S G Lynch, L S Middleton, and L M Harlan Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms Multiple Sclerosis, January 1, 2007; 13(1): 25 - 32. [Abstract] [PDF]

				R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers Neurology, May 9, 2006; 66(9): 1373 - 1383. [Abstract] [Full Text] [PDF]

				M Pinholt, J L Frederiksen, P S Andersen, and M Christiansen Apo E in multiple sclerosis and optic neuritis: the Apo E-o4 allele is associated with progression of multiple sclerosis Multiple Sclerosis, October 1, 2005; 11(5): 511 - 515. [Abstract] [PDF]

				E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al. Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions Arch Neurol, September 1, 2005; 62(9): 1345 - 1356. [Abstract] [Full Text] [PDF]

				N. Norgren, P. Sundstrom, A. Svenningsson, L. Rosengren, T. Stigbrand, and M. Gunnarsson Neurofilament and glial fibrillary acidic protein in multiple sclerosis Neurology, November 9, 2004; 63(9): 1586 - 1590. [Abstract] [Full Text] [PDF]

				B Zakrzewska-Pniewska, M Styczynska, A Podlecka, R Samocka, B Peplonska, M Barcikowska, and H Kwiecinski Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(3): 266 - 271. [Abstract] [PDF]

				J N. Zwemmer, T van Veen, L van Winsen, G J van Kamp, F Barkhof, C H Polman, and B M. Uitdehaag No major association of A poE genotype with disease characteristics and MRI findings in multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(3): 272 - 277. [Abstract] [PDF]